• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

    6/24/25 7:00:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email

    Guidelines include the next-generation targeted therapy with Preferred status across all lines of therapy in advanced setting, including patients with brain metastases and acquired resistance mutations

    Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI™) has been added as a Preferred Agent in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Non-Small Cell Lung Cancers (NSCLC), updated on June 20. Specifically, the NCCN Guidelines® now include taletrectinib (IBTROZI) as a Preferred Agent for both first-line and subsequent therapy for ROS1-positive NSCLC, including specific recommendations for those with brain metastases and resistance mutations.

    "We are very pleased the NCCN acted with such urgency to review and update the NCCN Guidelines to include taletrectinib (IBTROZI) as a preferred option for advanced ROS1-positive NSCLC across treatment lines, with particular recognition of benefit for patients with brain metastases and those with acquired resistance after first-line therapy," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "These updates address critical needs for patients across their treatment journeys, especially with the prevalence of CNS involvement for those living with ROS1+ NSCLC. Additionally, this version builds further upon a previous guideline update that importantly highlights preferred utilization of ROS1-targeted agents instead of immunotherapy and chemotherapy for these patients."

    The U.S. Food and Drug Administration (FDA) approved taletrectinib (IBTROZI) on June 11 for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Taletrectinib (IBTROZI) is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) designed to address some of the outstanding challenges of treating the disease.

    ROS1+ NSCLC is a rare and aggressive form of lung cancer, accounting for approximately 2% of new NSCLC cases, or about 3,000 new diagnoses of advanced disease annually in the U.S. The median age at diagnosis for patients with this type of lung cancer is approximately 50 years old, and the disease is more likely to occur in people who have never smoked. Brain metastases are common and a leading cause of disease progression and mortality in this population.

    The NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

    The updated NCCN Guidelines are available at www.nccn.org.

    About ROS1+ NSCLC

    Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing CNS metastases. Despite recent progress for patients with ROS1+ NSCLC, there remains a need for more effective and tolerable treatment options.

    About IBTROZI

    IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor therapy approved for the treatment of adult patients with advanced ROS1-positive non-small cell lung cancer. Learn more at IBTROZI.com.

    About the TRUST Clinical Program

    The TRUST clinical program evaluating IBTROZI for the treatment of adult patients with advanced ROS1+ NSCLC included two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, which enrolled 173 patients, and TRUST-II (NCT04919811), a global study, which enrolled 164 patients. The primary endpoint of these registrational studies is confirmed objective response rate (cORR) as assessed by an independent review committee (IRC). Secondary endpoints include intracranial cORR, duration of response, progression-free survival, and safety.

    Indication

    IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).

    IMPORTANT SAFETY INFORMATION FOR IBTROZITM (taletrectinib)

    WARNINGS AND PRECAUTIONS

    Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).

    Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.

    Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.

    Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).

    ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.

    QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.

    In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.

    Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.​

    Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.

    Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).

    Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.

    Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.

    Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.

    ADVERSE REACTIONS

    Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). ​

    The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%). ​

    DRUG INTERACTIONS

    • Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.
    • Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI.

    OTHER CONSIDERATIONS

    • Pregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity. ​
    • Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.
    • Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.
    • Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.
    • Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation.

    Please see accompanying full Prescribing Information.

    About Nuvation Bio

    Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes IBTROZI (taletrectinib), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor for glioma; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor.

    Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).

    Forward-Looking Statements

    Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, the needs of patients with ROS1-positive NSCLC and our belief that placement of IBTROZI in the updated NCCN Guidelines for NSCLC reflects the recognition of benefit for patients with brain metastases and those with acquired resistance after first-line therapy. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to whether Nuvation Bio is successful in commercializing IBTROZI; the challenges associated with conducting drug discovery and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; whether Nuvation Bio meets its post-marketing requirements and commitments for IBTROZI; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on May 7, 2025 under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250624605890/en/

    Media and Investor Contacts



    Nuvation Bio Investor Contact

    [email protected]



    Nuvation Bio Media Contact

    [email protected]

    Get the next $NUVB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    8/2/2022Buy → Neutral
    BTIG Research
    5/4/2022$14.00Buy
    H.C. Wainwright
    10/15/2021$16.00Buy
    BTIG Research
    More analyst ratings

    $NUVB
    SEC Filings

    See more
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      6/11/25 4:24:16 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      5/23/25 2:21:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nuvation Bio Inc.

      SCHEDULE 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      5/12/25 10:36:17 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

      Guidelines include the next-generation targeted therapy with Preferred status across all lines of therapy in advanced setting, including patients with brain metastases and acquired resistance mutations Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI™) has been added as a Preferred Agent in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Non-Small Cell Lung Cancers (NSCLC), updated on June 20. Specifically, the NCCN Guidelines® now include taletrectinib (IBTROZI) as a Preferred Agent for both first-li

      6/24/25 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

      Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (

      6/11/25 1:20:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

      Presentation will highlight the comparable efficacy and safety of taletrectinib across pivotal studies and different ethnicities and world regions The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented at the upcomin

      5/21/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:15 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:21 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:19 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Nuvation Bio with a new price target

      Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00

      4/23/25 8:17:12 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously

      3/27/24 8:16:27 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by BTIG Research with a new price target

      BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00

      3/26/24 7:48:54 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:15 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:21 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:19 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

      Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

      10/7/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

      Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

      5/14/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

      Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

      3/28/24 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Financials

    Live finance-specific insights

    See more
    • U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

      Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (

      6/11/25 1:20:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will

      4/22/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      11/12/24 10:32:11 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

      SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

      10/18/24 4:15:55 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Nuvation Bio Inc.

      SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

      9/10/24 4:51:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care